Profile data is unavailable for this security.
About the company
Medrx Co., Ltd. is a Japan-based Company principally engaged in the research and development of pharmaceutical products. The Company produces new medicines based on percutaneous absorption formulation technology. The Company has pharmaceutical formulation technology, including percutaneous absorbent technology of ionic liquid transdermal system (ILTS) using characteristics of ionic liquid, and percutaneous absorbent technology of nano-sized colloid transdermal system (NCTS) using Nano colloidization technology of drug. Based on the technology, The Company aims to maximize drug efficacy, reduce side effects, prevent forgetting to drink, and to administer to patients who are difficult to orally administer, and to produce medicines with new added value.
- Revenue in JPY (TTM)22.57m
- Net income in JPY-770.66m
- Incorporated2002
- Employees22.00
- LocationMedrx Co Ltd431-7, NishiyamaHIGASHIKAGAWA-SHI 769-2712JapanJPN
- Phone+81 879233071
- Fax+81 879233072
- Websitehttps://www.medrx.co.jp/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Kubota Pharmaceutical Holdings Co Ltd | 39.74m | -1.39bn | 4.17bn | 12.00 | -- | 1.78 | -- | 104.82 | -24.82 | -24.82 | 0.711 | 41.58 | 0.0118 | 0.3815 | 26.89 | 3,312,000.00 | -41.32 | -36.51 | -45.53 | -39.47 | 72.88 | -- | -3,492.38 | -13,528.87 | 8.97 | -- | 0.0555 | -- | 383.24 | -- | 26.11 | -- | 24.38 | -- |
| Renascience Inc | 194.17m | -258.34m | 4.64bn | 4.00 | -- | 2.89 | -- | 23.90 | -20.32 | -20.32 | 15.27 | 126.40 | 0.089 | -- | -- | 48,541,250.00 | -11.84 | -- | -12.49 | -- | 85.31 | -- | -133.05 | -- | -- | -- | 0.1814 | -- | 93.11 | -- | 23.07 | -- | -- | -- |
| Immuno-Biological Laboratories Co., Ltd. | 816.70m | 186.69m | 4.85bn | 57.00 | 25.99 | 3.83 | -- | 5.94 | 20.05 | 20.05 | 87.69 | 135.86 | 0.535 | 0.9358 | 4.53 | 14,328,090.00 | 12.23 | -13.97 | 14.68 | -16.39 | 63.34 | 57.73 | 22.86 | -39.23 | 3.65 | -- | 0.1572 | -- | 2.78 | 0.8924 | 164.44 | -- | -- | -- |
| Delta-Fly Pharma Inc | 0.00 | -1.43bn | 5.02bn | 13.00 | -- | 4.07 | -- | -- | -197.24 | -197.24 | 0.00 | 149.78 | 0.00 | -- | -- | 0.00 | -120.07 | -67.70 | -141.25 | -72.02 | -- | -- | -- | -877.69 | -- | -243.15 | 0.00 | -- | -- | -- | -7.57 | -- | -9.04 | -- |
| Solasia Pharma KK | 408.00m | -1.18bn | 6.00bn | 24.00 | -- | 3.00 | -- | 14.70 | -6.96 | -6.96 | 2.40 | 10.01 | 0.1432 | 2.01 | 3.06 | 17,000,000.00 | -41.50 | -48.57 | -53.67 | -58.83 | 51.23 | 71.01 | -289.71 | -300.89 | 1.68 | -400.00 | 0.2327 | -- | -43.50 | 14.18 | 56.36 | -- | -- | -- |
| COSMO BIO COMPANY, LIMITED | 9.46bn | 408.00m | 6.31bn | 155.00 | 14.91 | 0.6836 | 11.11 | 0.6672 | 69.94 | 69.94 | 1,620.67 | 1,525.81 | 0.8484 | 6.09 | 2.87 | 61,000,000.00 | 3.80 | 5.62 | 4.54 | 6.72 | 33.82 | 37.40 | 4.48 | 6.23 | 5.15 | -- | 0.0021 | 33.53 | -2.23 | 5.16 | -14.51 | 11.20 | -8.03 | 16.47 |
| MEDRx Co Ltd | 22.57m | -770.66m | 6.79bn | 22.00 | -- | 3.18 | -- | 300.65 | -20.97 | -20.97 | 0.6128 | 47.84 | 0.0143 | 0.00 | 4.22 | 1,025,955.00 | -48.80 | -58.15 | -50.27 | -62.23 | 100.00 | 95.70 | -3,414.38 | -1,526.17 | 43.57 | -- | 0.00 | -- | -50.35 | 28.60 | 16.04 | -- | -55.29 | -- |
| NIPPON CHEMIPHAR CO., LTD. | 30.75bn | -180.00m | 6.85bn | 887.00 | -- | 0.3141 | 5.36 | 0.2227 | -49.89 | -49.89 | 8,520.20 | 5,115.78 | 0.6268 | 2.14 | 2.70 | 34,665,160.00 | -0.3689 | 0.7482 | -0.5204 | 1.08 | 25.17 | 30.99 | -0.5887 | 1.13 | 1.53 | -- | 0.4791 | 50.73 | -2.57 | -2.10 | -153.10 | -- | 24.62 | -12.94 |
| Perseus Proteomics Inc | 100.40m | -1.10bn | 7.13bn | 25.00 | -- | 4.13 | -- | 71.01 | -93.74 | -93.74 | 8.52 | 117.15 | 0.0471 | 3.35 | 8.55 | 4,016,080.00 | -51.85 | -41.34 | -54.94 | -43.43 | 87.33 | 91.72 | -1,100.04 | -891.26 | 12.77 | -- | 0.00 | -- | 6.58 | -18.31 | -40.34 | -- | 60.30 | -- |
| Symbio Pharmaceuticals Ltd | 4.64bn | -2.74bn | 7.99bn | 109.00 | -- | 1.11 | -- | 1.72 | -66.88 | -66.88 | 113.80 | 156.38 | 0.5439 | 2.76 | 5.14 | 42,594,130.00 | -32.15 | -19.18 | -35.33 | -23.62 | 78.38 | 65.84 | -59.12 | -24.32 | 10.43 | -- | 0.00 | -- | -44.15 | 7.82 | -266.45 | -- | 42.39 | -- |
| K Pharma Inc | 500.00m | -221.98m | 8.47bn | 15.00 | -- | 2.95 | -- | 16.94 | -18.94 | -18.94 | 43.04 | 247.43 | 0.2095 | 4.49 | -- | 33,333,330.00 | -9.30 | -- | -9.83 | -- | 91.00 | -- | -44.40 | -- | 42.60 | -- | 0.00 | -- | -- | -- | 166.34 | -- | -- | -- |
| Wakamoto Pharmaceutical Co Ltd | 7.74bn | 108.96m | 8.85bn | 274.00 | 80.91 | 0.733 | 17.00 | 1.14 | 3.14 | 3.14 | 222.97 | 346.51 | 0.4971 | 2.09 | 2.57 | 28,242,430.00 | 0.70 | -2.28 | 0.8046 | -2.64 | 46.52 | 51.00 | 1.41 | -3.97 | 3.85 | -- | 0.0083 | -- | -10.65 | -6.35 | -21.19 | -- | 4.93 | -- |
| CanBas Co Ltd (Parent) | 0.00 | -1.09bn | 9.61bn | 12.00 | -- | 3.21 | -- | -- | -64.47 | -64.47 | 0.00 | 166.10 | 0.00 | -- | -- | 0.00 | -43.91 | -65.86 | -45.99 | -79.11 | -- | -- | -- | -1,094.10 | -- | -- | 0.00 | -- | -- | -- | -45.41 | -- | -- | -- |
| Kohjin Bio Co Ltd | 4.77bn | 384.98m | 9.61bn | 159.00 | 20.37 | 2.34 | 14.04 | 2.01 | 92.30 | 92.30 | 1,122.07 | 802.50 | -- | -- | -- | 30,000,600.00 | -- | -- | -- | -- | 39.44 | -- | 8.07 | -- | 1.14 | -- | 0.4249 | -- | 0.5715 | -- | -53.61 | -- | -- | -- |
Data as of Jul 05 2024. Currency figures normalised to Medrx Co Ltd's reporting currency: Japanese Yen JPY
1.29%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Evolution Capital Management LLCas of 15 May 2024 | 401.30k | 0.91% |
| Simplex Asset Management Co., Ltd.as of 06 Jun 2024 | 164.40k | 0.37% |
Data from 21 Jun 2024 - 25 Jun 2024Source: FactSet Research Systems Inc.
